#Blood Screening Market size

[industrynewsupdates]

Blood Screening Market Analysis, Opportunities And Forecast Report 2024-2030

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly. 

Blood Screening Market Segmentation

Grand View Research has segmented the global blood screening market based on technology, product, and region:

Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Nucleic Acid Amplification Test (NAT)

• ELISA

• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

• Next Generation Sequencing

• Western Blotting

Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagent

• Instrument

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global embolic protection devices market size was valued at USD 612.9 million in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030. 

• The global covered stent market size was estimated at USD 1.13 billion in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030. 

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.

For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.

Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.

Key Blood Screening Companies:

• Abbott

• Danaher Corporation (Beckman Coulter)

• Becton Dickinson and Company

• Bio-Rad Laboratories, Inc.

• Hoffman-La Roche Ltd.

• Grifols, S.A.

• Ortho-Clinical Diagnostics, Inc.

• Siemens Healthcare GmbH

• Thermo Fisher Scientific, Inc.

• SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research. 

[healthcaremarketanalysis]

The report "Blood Screening Market by Product (Reagent & Kits, Instrument, Software), Technology (NAT, (Real-Time PCR), ELISA (Chemiluminescence Immunoassay), Rapid Test, Western Blot), End User (Blood Bank, Hospital), & Region - Global Forecast to 2028", is projected to reach USD 3.4 billion by 2028 from USD 2.4 billion in 2023, at a CAGR of 7.2% during the forecast period. Growth in this market is mainly driven by the growing requirement for donated blood, the rising number of blood donations around the world, and the ever-increasing infectious diseases. However, operational barriers and the high cost of Blood screening instruments is likely to hamper the growth of blood screening market.

[aadeshmmr]

The examination of the COVID-19 lock-down's effects on market leaders', followers', and disruptors' revenue is included in the research.

[nvuy]

nuvy. nuvy have you heard of the boothill leaks.

YES i did *salutes*

boothill story leaks under cut;

girl dad girl dad

soooo what about boothill falling in love with a single parent with a daughter hmm hmm

like god if he doesn’t just accidently run into the kid and she squeals over him because “hey!! cool robot man!!” and you chase her down and apologise.

he freezes, because your daughter looks so much like his did.

same hair colour, same eye colour, same energy that he could barely keep up with, just learning to walk on two feet properly and string together words to form simple sentences.

it absolutely destroys him. in the worst and best way possible. especially since your daughter practically develops an admiration for him on the spot, begs to be carried, and you’re confused because “sweetie, you shouldn’t be talking to strangers.”

like like.,,,, example……..

Something small and warm wraps around his hand and Boothill glances up quickly from his lap.

There was a little girl searching for his fingers, barely three years old by the looks of it. Pretty tresses of black hair flowing in the wind near the shoreline, sniffling and barely standing on short wobbly legs.

“I need help,” she hiccups, and Boothill melts on the spot. So small and helpless, like a baby bird away from its mother’s nest. “I can’t find my–”

And of course, he stands up, dusts off his pants, and offers her his hand. He guides her away from the beach back towards the market where crowds of people swarm the stalls.

It’s nighttime, cold, and definitely no place for a little girl to be by herself.

“What’s your parents look like, princess?”

He busies himself searching for any targets that would make sense given the girl’s prattling of your appearance down to the colour of your shoes—“White. Like mine.” Hers light up purple with each step she takes—too many faces, too many people.

He stands to give up when he hears somebody frantically running around like a lunatic to every single store, asking if they’ve seen a little girl with light up sneakers wandering about.

“Calm down. I’m sure she’s around here somewhere,” he heard one of the assistants try.

Another shopkeeper offers a pitiful frown and shakes their head.

Boothill nudges the girl, squeezing her small hand in his, careful of his strength around fragile bones. “Is that them?”

She quickly wipes the tears from her face. She then nods and takes off into a sprint to lunge at you, still sobbing when she wraps her arms around your leg.

You sigh in relief and scoop her up into your arms.

Boothill then has an entire conundrum in the middle of the market square. For one, your daughter is waving him over with a smile on her face. Two, you looked like you were about two seconds away from passing out in shock. Your clothes are askew, hair a mess, face flushed and yet simultaneously drained of blood.

He steps closer anyway, though hesitantly. He can’t say no to the little thing whose grin has now grown double the size of her face.

“This is the man that helped me,” she explained softly to you, pointing at him with a small finger.

You scanned him over.

For a moment, he thought you were going to turn around and book it in the other direction. A random ‘robot man’ in the centre of the town square was probably the least most inviting thing he could’ve been. Not to mention he had been sitting at the docks for so long staring out into the water he knew his hair had been tossed wildly from the wind.

Not that you appeared anymore put together.

Instead, you grab his face with a free hand and kiss him on the cheek.

“Thank you,” you whispered hoarsely.

He almost damn near blue screens. The words ‘anything for you’ fight to come forth out of his throat.

Instead, he lets out a garbled noise before he clears his throat. “Of course. Couldn’t let the little princess run too far.” He teased your daughter with a tap to her nose.

She grabs his finger and presses the pads of her own across the metal rivets and joints like she’s studying them curiously.

Your daughter stared up at you with giant puppy eyes, still holding his hand. “Can we keep him?”

It was your turn to make a weird noise, spluttering with your face heating up. “You can’t keep people.”

All the while, Boothill was staring at you as you chastised her with hot cheeks.

No spouse by the looks of it—nor had the little princess mentioned somebody else. He knew kids liked to ramble on about their parents.

Well, his daughter did. Something cold and metallic turned in his stomach. She used to think her dad was a hero.

He wondered if she still would.

No ring on your finger. Adoration was such a gentle expression on your face, and the way you held her so firmly, yet so delicately, said it all.

Oh, if he wasn’t completely head over heels from the very beginning.

the angst potential. The angst potential. Theeee angst potential. i’m gritting my teeth.

i’m going insan e

[tamanna31]

Blood Screening Market 2023- Business Planning Research and Resources, Revenue, and Forecasts 2030

Blood Screening Market Size & Trends

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly. 

Blood Screening Market Segmentation

Grand View Research has segmented the global blood screening market based on technology, product, and region:

Technology Outlook (Revenue, USD Million, 2018 - 2030)

Nucleic Acid Amplification Test (NAT)

ELISA

Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

Next Generation Sequencing

Western Blotting

Product Outlook (Revenue, USD Million, 2018 - 2030)

Reagent

Instrument

Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Europe

UK

Germany

France

Italy

Spain

Sweden

Norway

Denmark

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Latin America

Brazil

Mexico

Argentina

Middle East and Africa

Saudi Arabia

South Africa

UAE

Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports.

The global embolic protection devices market size was valued at USD 612.9 million in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030. 

The global covered stent market size was estimated at USD 1.13 billion in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030. 

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.

For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.

Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.

Key Blood Screening Companies:

Abbott

Danaher Corporation (Beckman Coulter)

Becton Dickinson and Company

Bio-Rad Laboratories, Inc.

Hoffman-La Roche Ltd.

Grifols, S.A.

Ortho-Clinical Diagnostics, Inc.

Siemens Healthcare GmbH

Thermo Fisher Scientific, Inc.

SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research. 

[creativeera]

DNA and RNA Sample Preparation Market is Estimated to Witness High Growth Owing to Increasing Adoption

The DNA and RNA sample preparation market involves processes associated with isolation, extraction, purification and quantification of nucleic acids DNA and RNA from various sources like tissues, blood, sperm, cells etc. for downstream applications in genomics, molecular diagnostics, personalized medicine and others. The sample preparation is a critical and initial step before conducting various genomic tests including Next Generation Sequencing, polymerase chain reaction and other assays. Growing awareness and adoption of precision medicine and genetic/molecular testing is driving demand for efficient nucleic acid isolation and downstream analysis.

The Global DNA and RNA Sample Preparation Market is estimated to be valued at US$ 2262.46 Mn in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast period 2024 To 2031. Key Takeaways Key players operating in the DNA and RNA sample preparation are Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., DiaSorin S.p.A, F. Hoffmann-La Roche, Miroculus, Inc., Illumina, Inc., PerkinElmer, Inc., QIAGEN, Sigma Aldrich Corp., Tecan Group AG, and Thermo Fisher Scientific, Inc. Growing prominence of personalized medicine is creating opportunities for development of new sample preparation methods and kits which can extract nucleic acids from various types of samples. Rising incidence of chronic and infectious diseases worldwide is increasing diagnostic testing which will propel sample preparation market growth. Global expansion of key market players through acquisitions and partnerships with regional diagnostic labs and research institutes will further augment market revenues. Market Drivers Increasing funding for Genomic and genetic research from government bodies as well as private sector is one of the key factors driving the DNA and RNA Sample Preparation Market Size. Government initiatives aimed at large scale population screening and clinical testing for various genetic disorders, infectious diseases and cancers are also creating demand for high throughput nucleic acid preparation. Growing geriatric population and rising healthcare spending in developing nations also provides growth opportunities for market players in the forecast period.

PEST Analysis Political: Laws and regulations imposed by governments for research using DNA and RNA samples could impact the market. Changes in healthcare policies will also have effects. Economic: Factors like GDP growth, income levels, healthcare spending will drive demand. Rise in research activities and focus on precision medicine boost the market. Social: Growing awareness about personalized medicine and importance of genetic testing are important. Social trends also promote preventive healthcare and wellness. Technological: Advancements in fields like next generation sequencing, lab automation, bioinformatics are key for market growth. Miniaturization and portability of equipment expand applications. Developments in sample collection and storage methods improve efficiency. Geographical regions where the market in terms of value is concentrated include North America and Europe. North America accounts for the largest share in the global market due to presence of well-established healthcare industry and research institutes. Europe also captures notable share due to growing biotech sector and research funding. The Asia Pacific region is projected to be the fastest growing market during the forecast period. This is attributed to factors such as increasing healthcare expenditure, growing awareness, expanding biotech industry and rising government investments in research. Countries like China, India offer growth opportunities as they focus on healthcare infrastructure development.

Get more insights on DNA And RNA Sample Preparation Market

Also read related article on Surgical Robots Market

Discover the Report for More Insights, Tailored to Your Language

French

German

Italian

Russian

Japanese

Chinese

Korean

Portuguese

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.

(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

[prognosysmedicalsystems]

Future Trends in X-Ray Technology: What’s Next? - An Article by Prognosys Medical System

X-ray technology has undergone remarkable advancements since its discovery in the late 19th century, transforming from rudimentary imaging systems to highly sophisticated diagnostic tools. As we move further into the digital age, the field of radiology continues to evolve, driven by emerging technologies and a growing demand for more precise, efficient, and patient-centered care. This article explores the future trends in X-ray technology, highlighting innovations that are shaping the future of medical imaging.

1. Artificial Intelligence (AI) Integration: AI is set to revolutionize X-ray imaging by enhancing the diagnostic capabilities of radiologists. AI algorithms are increasingly being integrated into imaging systems to assist in reading X-rays, detecting abnormalities, and providing more accurate diagnoses. Machine learning models trained on vast datasets can identify patterns and anomalies that may be missed by the human eye, leading to earlier detection of conditions such as cancer, fractures, or lung diseases.

For instance, AI-driven software can analyze chest X-rays to screen for signs of COVID-19, tuberculosis, or pneumonia with high accuracy. In addition to improving diagnostic precision, AI can also help reduce the workload on radiologists by automating routine tasks, enabling faster image interpretation and reporting.

According to recent Study done by Straits Research shows that the global AI-enabled X-Ray imaging solutions market size was valued at USD 387.4 million in 2023. It is estimated to reach USD 2,218.11 million by 2032, growing at a CAGR of 21.60% during 2024-2032.

2. 3D and 4D X-Ray Imaging: Traditional 2D X-rays provide valuable information, but they often lack the depth required for complex diagnoses. Enter 3D and 4D imaging, which offer a more detailed view of anatomical structures. 3D X-ray technology, such as Cone Beam Computed Tomography (CBCT), is already being used in dental and orthopedic applications. This allows for more precise visualization of bones and teeth, facilitating accurate surgical planning and treatment.

4D X-ray imaging takes this a step further by incorporating the dimension of time, allowing for real-time visualization of moving body parts. This is particularly useful in dynamic studies such as cardiac imaging, where the movement of the heart and blood vessels can be observed and analyzed in detail.

According to recent Study done by Future Market Insights, Inc. shows that the global advanced (3D/4D) visualization systems market is anticipated to witness an increase in revenue from US$ 731.7 million in 2023 to US$ 1,139.9 million by 2028 which indicates the 3D and 4D X-Ray Imaging systems growth in coming years.

3. Low-Dose and Ultra-Low Dose Imaging: As concerns about radiation exposure continue to grow, the development of low-dose and ultra-low dose X-ray systems is a top priority. Advanced image processing techniques and detector technologies are enabling manufacturers to significantly reduce radiation doses without compromising image quality.

The advent of low-dose systems is especially important in pediatric imaging and for patients requiring multiple scans over time, such as those undergoing cancer treatment. These systems ensure patient safety while maintaining diagnostic accuracy, addressing a key challenge in the widespread use of X-rays in healthcare.

4. Portable and Point-of-Care X-Ray Systems: Portability is a critical trend in medical technology, and X-ray systems are no exception. Mobile and handheld X-ray units are becoming more compact, lightweight, and efficient, allowing for greater flexibility in imaging patients in various settings. Portable X-rays are especially useful in emergency rooms, intensive care units (ICUs), and for bedside imaging in hospitals.

Point-of-care X-ray systems enable immediate diagnosis and treatment, minimizing delays in patient care. In disaster zones or rural areas where access to medical facilities is limited, portable X-ray units can play a vital role in delivering life-saving care.

 In July 2022, MIOT hospital, based in Chennai, India, acquired mobile full-body CT scan equipment to allow real-time imaging during surgeries. Thus, the increase in the adoption of point-of-care imaging technology by end-users. Which shows the Portable and Point-of-Care X-Ray Systems adoption trends.

5. Spectral Imaging and Photon-Counting Detectors: Spectral imaging, also known as dual-energy X-ray imaging, is a rapidly emerging technology that provides enhanced image contrast by capturing multiple energy levels of X-rays. This technique allows for better differentiation of tissues and materials, offering more detailed insights into soft tissue, bone, and even foreign objects.

Photon-counting detectors, another innovation in X-ray technology, improve image resolution and contrast by counting individual photons rather than measuring the overall energy absorbed. This leads to clearer, more detailed images while further reducing radiation exposure. These detectors are expected to become integral components of next-generation CT scanners and X-ray systems.

6. Teleradiology and Cloud-Based Imaging: As healthcare becomes more connected, the need for efficient image sharing and collaboration has grown. Teleradiology, the practice of transmitting radiological images from one location to another for diagnosis and consultation, is already widely used. However, advancements in cloud-based imaging platforms are set to take this to the next level.

Cloud technology allows radiologists and clinicians to access and interpret images remotely in real time, improving workflow efficiency and enabling faster decision-making. These systems also offer secure storage, easy retrieval, and seamless sharing of images across multiple healthcare facilities, ensuring better coordination of care.

7. Hybrid Imaging Systems: Hybrid imaging, which combines two or more imaging modalities into a single system, is gaining traction in the medical field. X-ray/CT hybrid systems, for example, provide the benefits of both conventional X-rays and computed tomography, delivering high-resolution images with the added detail of cross-sectional views.

Such systems are particularly valuable in complex cases where a more comprehensive view of the anatomy is needed. Hybrid imaging enhances diagnostic accuracy, reduces the need for multiple scans, and minimizes patient exposure to radiation by consolidating procedures.

Conclusion The future of X-ray technology is poised for significant transformation, driven by advances in AI, 3D and 4D imaging, portable systems, and spectral imaging. These trends are not only enhancing the accuracy and efficiency of diagnostic imaging but also improving patient safety and care. As these technologies continue to evolve, X-ray systems will become even more integral to healthcare, offering unprecedented opportunities for early detection, precision treatment, and better patient outcomes.

The fusion of innovation and medical imaging holds the promise of a brighter future for radiology and diagnostics.

Click the links to Know More about Prognosys Medical Systems Radiology Product Range.

Contact us for more information:

– Content Team Prognosys Medical Systems

marketing@prognosysmedical.com

[trendtrackershq]

The Impact of Personalized Medicine on the Blood Preparation Market

Introduction

The blood preparation market is undergoing a transformative shift, driven by advancements in personalized medicine. Personalized medicine, which tailors medical treatment to the individual characteristics of each patient, is reshaping how blood products are prepared, tested, and administered. This article explores the impact of personalized medicine on the blood preparation market, including how it influences blood product development, treatment protocols, and overall market dynamics.

Download Free Sample: https://www.nextmsc.com/blood-preparation-market/request-sample

Understanding Personalized Medicine

Personalized medicine, also known as precision medicine, leverages genetic, environmental, and lifestyle information to customize healthcare for individual patients. Unlike the traditional one-size-fits-all approach, personalized medicine aims to deliver more effective and targeted treatments by considering a person’s unique biological makeup. This approach is particularly significant in fields such as oncology, cardiology, and hematology, where personalized strategies can drastically improve patient outcomes.

The Blood Preparation Market: An Overview

The blood preparation market encompasses the collection, processing, storage, and distribution of blood and its components. This market is crucial for various medical treatments, including surgeries, trauma care, and chronic disease management. Blood preparation involves several key processes:

Collection: Blood is collected from donors using sterile techniques.

Processing: Blood is separated into its components, such as red blood cells, plasma, and platelets.

Storage: Components are stored under specific conditions to maintain their viability.

Distribution: Prepared blood products are distributed to hospitals and clinics for patient use.

Personalized Medicine's Influence on Blood Preparation

Tailored Blood Products

One of the most significant impacts of personalized medicine on blood preparation is the development of tailored blood products. Traditional blood products are generic and may not be optimal for every patient. Personalized medicine aims to refine these products based on individual patient needs.

Genotype-Specific Blood Products: Advances in genetic testing allow for the identification of specific genetic markers in patients. Blood products can now be matched to these markers to minimize adverse reactions and improve efficacy. For instance, blood transfusions can be customized to match the recipient’s genetic profile, reducing the risk of alloimmunization—a condition where the recipient's immune system attacks transfused blood cells.

Customized Platelet Therapy: Platelets play a critical role in blood clotting, and their effectiveness can vary based on genetic factors. Personalized medicine enables the preparation of platelet concentrates that are matched to the patient's genetic profile, enhancing their therapeutic benefits and reducing complications.

Enhanced Testing and Screening

Personalized medicine has also led to advancements in blood testing and screening. These advancements improve the accuracy of blood product matching and safety.

Advanced Genetic Screening: Modern genetic screening techniques can identify potential incompatibilities between donors and recipients. This allows for more precise matching of blood products, reducing the risk of adverse reactions and improving overall treatment outcomes.

Molecular Diagnostics: The integration of molecular diagnostics into blood preparation protocols enables the detection of specific biomarkers associated with diseases. This information helps in customizing blood products and treatments, especially for patients with complex conditions such as cancer or autoimmune disorders.

Precision Blood Banking

Personalized medicine is driving the evolution of blood banks towards a more precision-oriented approach. Traditional blood banks store a wide range of blood products without considering individual patient needs. However, the rise of personalized medicine is leading to:

Targeted Blood Collection: Blood banks are increasingly using genetic and health data to collect and store blood products that meet specific patient requirements. This ensures that the blood products are not only compatible but also tailored to the patient’s unique medical profile.

Smart Inventory Management: Advanced data analytics and AI are being employed to manage blood inventories more effectively. These technologies analyze patient data and predict future demand for specific blood products, optimizing inventory levels and reducing waste.

Advances in Blood Preparation Technologies

The integration of personalized medicine has spurred innovation in blood preparation technologies. New technologies are emerging to enhance the efficiency and safety of blood processing.

Automated Blood Separation: Automation in blood separation technology allows for more precise and consistent processing of blood components. These systems can be programmed to account for individual patient needs, ensuring that blood products are prepared to exact specifications.

Cell Therapy and Regenerative Medicine: Personalized medicine is closely linked with advancements in cell therapy and regenerative medicine. Techniques such as stem cell therapy and gene editing are being used to create customized blood products, such as genetically modified blood cells, which offer new treatment possibilities for patients with genetic disorders or chronic diseases.

Market Dynamics and Future Outlook

The blood preparation market is evolving rapidly due to the influence of personalized medicine. Several key trends are shaping the future of this market:

Increased Investment in R&D

The rise of personalized medicine is driving significant investment in research and development (R&D) within the blood preparation industry. Companies are investing in new technologies, genetic testing, and innovative processing techniques to stay competitive and meet the growing demand for tailored blood products.

Regulatory and Ethical Considerations

The integration of personalized medicine into blood preparation also brings about regulatory and ethical challenges. Ensuring the safety and efficacy of customized blood products requires rigorous testing and compliance with regulatory standards. Additionally, ethical considerations around genetic privacy and consent are crucial as personalized medicine continues to advance.

Growing Market Demand

The demand for personalized blood products is expected to grow as more patients and healthcare providers recognize the benefits of customized treatments. This growing demand is likely to drive market expansion and create new opportunities for companies in the blood preparation sector.

Conclusion

The impact of personalized medicine on the blood preparation market is profound and multifaceted. By tailoring blood products and treatments to individual patient needs, personalized medicine enhances the effectiveness and safety of blood-related therapies. Advances in genetic testing, targeted blood banking, and innovative technologies are reshaping how blood products are prepared and administered. As personalized medicine continues to evolve, it will undoubtedly drive further changes in the blood preparation market, leading to more precise, efficient, and patient-centric healthcare solutions.

[poonamcmi]

Colorectal Cancer Screening Market Primed for Growth due to Rising Disease Prevalence

The colorectal cancer screening market involves various procedures and diagnostic tests for early detection and prevention of colorectal cancer. Some common screening methods include fecal occult blood tests, flexible sigmoidoscopy, double-contrast barium enema, and colonoscopy. Colorectal cancer screening helps detect precancerous polyps or early stage cancer that can often be treated successfully. It also aids in lowering the incidence and mortality of this preventable disease.

The global colorectal cancer screening market is estimated to be valued at US$ 15.44 Bn in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the colorectal cancer screening market are Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Siemens Healthineers AG, Quidel Corporation, Novigenix SA, Hemosure Inc., Exact Sciences Corp., Epigenomics Inc., Olympus Corporation, Clinical Genomics Technologies Pty Ltd., Exact Sciences Corporation, Clinical Genomics, Guardant Health, Inc., Hemosure Inc., and Geneoscopy, Inc. These players are focused on launching advanced and easy-to-use screening tests to expand their presence.

The Colorectal Cancer Screening Market Size for players to leverage the growing awareness about early detection and increase screening rates in developing countries. Companies are engaging in partnerships and collaborations to penetrate developing markets and make screening accessible to a wider population.

Globally, there is an increasing focus on population-based screening programs to reduce the burden of colorectal cancer. Several regions have implemented organized screening programs through healthcare facilities. Meanwhile, growing pilot programs in Asian and Latin American countries indicate the potential for market expansion. Market Drivers

The rapid rise in colorectal cancer incidence worldwide due to lifestyle changes, obesity, and Colorectal Cancer Screening Market Size And Trends It is estimated that the number of new cases diagnosed each year will increase by 60% by 2030. Growing disease prevalence enhances the need for widespread screening practices to detect cancer at treatable stages. Additionally, increasing reimbursement for FDA-approved screening tests, favorable government initiatives, and rising awareness about early detection are supporting the adoption of screening worldwide. PEST Analysis Political: Government regulations and healthcare reforms impact the adoption of colorectal cancer screening tests. Favorable reimbursement policies can boost the market growth. Economic: Rising healthcare expenditures and growing disposable incomes encourage people to opt for preventive healthcare check-ups including colorectal cancer screening tests. Social: Increasing awareness about early detection benefits, changing lifestyles, and growing geriatric population drive the demand for colorectal cancer screening. Technological: Advancements in biopsy techniques, endoscopy devices, diagnostic platforms enable detection of colorectal cancer at an early stage. Novel non-invasive tests based on blood, stool and CSF analysis are gaining traction.

Colorectal cancer screening market in terms of value is highly concentrated in developed regions like North America and Western Europe due to established healthcare infrastructure and widespread awareness. The United States dominates the market owing to favorable reimbursement policies and regular screening recommendations.

Asia Pacific is recognized as the fastest growing regional market for colorectal cancer screening attributed to rising healthcare spending, growing number of screening programs, and increasing incidence of colorectal cancer cases especially in China, Japan and India. Improving diagnostic capabilities and economic development are expected to boost early detection in Asia Pacific over the forecast period. Get More Insights On, Colorectal Cancer Screening Market About Author: Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163

[healthcaremarketanalysis]

Blood Screening Market worth $3.4 billion by 2028

Blood Screening Market in terms of revenue was estimated to be worth $2.4 billion in 2023 and is poised to reach $3.4 billion by 2028, growing at a CAGR of 7.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growth in this market is mainly driven by the growing requirement for donated blood, the rising number of blood donations around the world, and the ever-increasing infectious diseases. However, operational barriers and the high cost of Blood screening instruments is likely to hamper the growth of blood screening market.

Download an Illustrative overview:

Browse in-depth TOC on "Blood Screening Market"

189 - Tables

45 - Figures

220 – Pages

The Reagents & Kits segment is expected to account for the largest share in 2022.

Based on product, the blood screening market is segmented into reagents & kits, instruments, and software & services. Increase in demand and continuous use of the reagents and kits during blood transfusion processes, post blood donations is responsible for the large segment of this segment.

Nucleic Acid Test segment aimed the highest share during the forecast period

The blood screening market is segmented into nucleic acid tests (NAT), serology/immunoassay, rapid tests, western blot assays, and next-generation sequencing (NGS). In 2022, the nucleic acid test (NAT) segment accounted for the largest share of the blood screening market. From all the other technologies, NAT provides high precision, sensitivity and accuracy for blood screening and therefore, holds the largest share.

North America has the upper hand in the global Blood screening market

By regional segmentation, the blood screening market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Africa. North America has the largest share and is continuing to dominate the blood screening market. The factors responsible for the large share of North America in this market are the increasing prevalence of infectious diseases, rising awareness in blood donations, and the growing healthcare system that is highly developed in the US and Canada.

Request Sample Pages:

Blood Screening Market Dynamics:

Drivers:

Increasing number of blood donations worldwide

Restraints:

Alternative technologies

Opportunities:

Emerging markets

Challenge:

High cost of blood screening technologies

Key Market Players:

The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott Laboratories, Inc. (US), Bio-Rad Laboratories, Inc. (US), Danaher (Beckman Coulter, Inc.) (US), bioMérieux (France),  Hologic (US), Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), DiaSorin (Italy), Siemens Healthineers (Germany), QuidelOrtho Corporation (US), Merck KGaA (Germany), Revvity (Earlier known as PerkinElmer Inc.) (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), J. Mitra & Co. Pvt. Ltd. (India) and Tulip Diagnostics (India).

Recent Developments:

In February 2023, Thermo Fisher Scientific Inc. (US) acquired TIB Molbiol (Germany), to expand its PCR test portfolio with a wide range of assays for infectious diseases.

In December 2021, Hologic, Inc. (US) launched Panther Trax for high-volume molecular testing.

In May 2021, Beckmann Coulter (US) launched SARS-CoV-2 IgG.

In September 2021, Roche Diagnostics (Switzerland) acquired TIB Molbiol Group (Germany). This acquisition will enhance Roche's broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.

Inquiry Before Buying:

Blood Screening Market Advantages:

Early Disease Detection: Blood screening allows for the early detection of various diseases, including infections, cancers, and chronic conditions. Early diagnosis often leads to more effective treatment and improved patient outcomes.

Preventative Medicine: It enables preventative measures by identifying risk factors and potential health issues before they become serious. This proactive approach can lead to better health management and reduced healthcare costs.

Transfusion Safety: Blood screening is vital in ensuring the safety of blood transfusions. It screens for infectious agents like HIV, hepatitis, and syphilis, minimizing the risk of transmitting diseases through donated blood.

Population Health Management: Blood screening data can be analyzed on a population level, helping healthcare systems identify trends, allocate resources more effectively, and develop targeted public health interventions.

Personalized Medicine: Advances in blood screening techniques, such as genetic testing, allow for personalized treatment plans tailored to an individual's genetic makeup, improving the effectiveness of therapies and reducing adverse reactions.

Research and Drug Development: Blood screening plays a pivotal role in clinical trials and drug development, providing insights into treatment efficacy, patient response, and biomarker identification.

Point-of-Care Testing: Point-of-care blood screening devices enable rapid diagnostics in diverse settings, from clinics to remote areas, facilitating timely medical interventions and reducing the burden on healthcare facilities.

Healthcare Efficiency: Automating blood screening processes increases efficiency, reduces human error, and speeds up results, allowing healthcare providers to make quicker and more informed decisions.

Global Health: Blood screening contributes to global health efforts by identifying and controlling infectious diseases, making it an essential tool in disease surveillance and outbreak management.

Improved Quality of Life: Ultimately, the blood screening market's advantages contribute to an overall improvement in the quality of life for individuals and communities, promoting better health and well-being.

In summary, the blood screening market's advantages encompass early detection, preventative care, safety, personalized medicine, research, and healthcare efficiency, all of which have a profound impact on healthcare outcomes and public health.

Related Reports:

[industryforecastnews]

Blood Cancer Diagnostics Market To Reach USD 16.04 Billion By 2030

Blood Cancer Diagnostics Market Growth & Trends

The global blood cancer diagnostics market size is expected to reach USD 16.04 billion by 2030, registering a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing incidence of blood malignancies, such as leukemia, lymphoma, and myeloma. The market is further expected to grow significantly due to the increasing elderly population, which is more susceptible to chronic diseases, including blood cancer. In addition, technological advancements, including NGS and other molecular diagnostic techniques, are improving the accuracy & efficiency of diagnosis, which is likely to drive the market over the forecast period.

Over the past decade, significant advancements have been made in approaches to blood cancer diagnostics, all aimed at reducing the growing incidence of diseases and their mortality. While these advancements have been well-documented to increase early cancer detection, there have been considerable advancements. For instance, NGS has enabled the analysis of the entire genome of cancer cells, providing insights into genetic mutations that guide precise diagnosis and tailored treatments. In October 2022, OGT, a Sysmex group, introduced a range of new offerings to augment its expanding NGS product suite. Notably, the SureSeq Myeloid Plus panel was designed to identify genetic mutations associated with various Myeloid disorders, enhancing the company’s capabilities in this critical area of research.

Molecular imaging techniques, such as SPECT/CT, PET, and flow cytometry, utilize molecular imaging agents to detect indicative molecular markers at different disease stages, aiding detection & monitoring. Such advancements in imaging technologies offer improved accuracy and early detection capabilities, driving the market. The global players are introducing automatic imaging tests and systems to boost their market share. For instance, in May 2023, Sysmex Corporation announced the launch of the Clinical Flow Cytometry System in Japan. The system includes Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products. This system enables laboratories to automate the entire process of flow cytometry testing, from sample preparation to the reporting of measurement results, contributing to higher efficiency & testing standardization.

Governments across the world have recognized the immense healthcare burden posed by rising incidences, including hematological malignancies such as leukemia & lymphoma. In response, many countries have launched comprehensive national cancer control programs that prioritize early detection and screening efforts. For instance, the American Association of Cancer Research recently launched the Beau Biden Cancer Moonshot initiative to accelerate cancer research and make preventive screening more accessible & affordable for U.S. citizens.

Some of the key players in the market are Illumina, InVivoScribe, Ipsogen (Qiagen), Asuragen(Bio-Techne), Danaher Corporation, Abbott, SkylineDx, Adaptive Technologies, Bio-Rad Laboratories and others. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in September 2023, Adaptive Technologies launched Epic integration for clonoSEQ, a molecular diagnostic test for MRD monitoring in blood cancers. This integration allows healthcare providers to order and review clonoSEQ test results directly within Epic's EHR system, streamlining clinical decision-making and improving patient care.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/blood-cancer-diagnostics-market-report

Blood Cancer Diagnostics Market Report Highlights

Based on product, the assay kits and reagents accounted for the largest revenue share of the blood cancer diagnostics market in 2023. This high share is attributable to assay kits & reagents being designed to detect specific biomarkers, genetic mutations, and other indicators, enabling healthcare professionals to diagnose & treat the disease more effectively

Based on tests, blood tests segment dominated the market and accounted for the largest share in 2023. This can be attributed to increasing innovation and availability of blood test kits for blood cancer detection

Based on end use, hospitals and clinics dominated the market with the largest share of blood cancer diagnostics market in 2023. This is attributable to growing demand in forensic labs and hospital medical labs for disease diagnosis, blood cell counts, blood typing. Furthermore, Developments in hospital laboratories are crucial to address the evolving needs of patients, and more hospitals aim to provide a wide range of services in their settings

North America dominated the market due to the presence of a large number of major market players, North America has a high prevalence of chronic diseases like leukemia These diseases require regular monitoring and diagnostic testing, fueling the demand for advanced diagnostic tools and technologies

Asia Pacific is expected to witness the fastest growth over the forecast period from 2024 to 2030, due to the presence of manufacturers with innovative devices manufacturing capabilities coupled with accelerated diagnostic research capabilities

Blood Cancer Diagnostics Market Segmentation 

Grand View Research has segmented the global blood cancer diagnostics market based on product, test, end use, and region:

Blood Cancer Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)

Instruments

Assay Kits and Reagents

Blood Cancer Diagnostics Test Outlook (Revenue, USD Million, 2018 - 2030)

Blood Tests

Imaging Tests

Biopsy

Molecular Test

Blood Cancer Diagnostics End Use Outlook (Revenue, USD Million, 2018 - 2030)

Hospitals and Clinics

Diagnostic Labs

Research Institutes

Blood Cancer Diagnostics Regional Outlook (Revenue in USD Million, 2018 - 2030)

North America

U.S.

Canada

Mexico

Europe

UK

Germany

France

Italy

Spain

Sweden

Denmark

Norway

Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

Latin America

Brazil

Argentina

Middle East and Africa

Saudi Arabia

South Africa

UAE

Kuwait

List Of Key Players in The Blood Cancer Diagnostics Market

Abbott

Illumina

InVivoScribe

Ipsogen (Qiagen)

Asuragen(Bio-Techne)

Danaher Corporation

Sequenta (Adaptive biotechnologies)

SkylineDx

Bio-Rad Laboratories

Alercell

Sophia Genetics

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/blood-cancer-diagnostics-market-report

[tamanna31]

Health Check-up Market - The Biggest Trends to watch out for 2023-2030

Health Check-up Industry Overview

The global health check-up market size was valued at USD 48.71 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.3% from 2023 to 2030.

The market growth is attributable to the increasing prevalence of chronic diseases, rising investments from government bodies to establish population medical screening initiatives, and the adoption of telemedicine & home-based services. For instance, in May 2023, the Indian Health Ministry launched a medical screening initiative for people with hypertension and diabetes. This initiative will provide standard care to around 75 million people suffering from non-communicable diseases by 2025.

Gather more insights about the market drivers, restrains and growth of the Health Check-up Market

Moreover, the introduction of telemedicine in general healthcare practices fueled the home-based testing market, while the healthcare ecosystem's digital connectivity framework powered the health check-up market during the COVID-19 pandemic. The increasing prevalence of life-threatening diseases is one of the key drivers for the industry. Additionally, non-communicable diseases such as diabetes, hypertension, cancer, and cardiovascular diseases are increasing, which often remain asymptomatic in the early stages. For instance, as per an AMGA article, more than 30% of the U.S. population suffers from prehypertension, increasing the chances of developing high blood pressure. Regular health check-up allows individuals to manage the condition effectively, as only 1 in 4 U.S. adults have their hypertension under control.

Additionally, government bodies are undertaking initiatives to screen the target population for different medical conditions. For instance, the U.S. Preventive Services Task Force (USPSTF) recommends yearly screening for adults aged 18 and older to manage blood pressure risks. Similarly, Middle Eastern economies have initiated medical screening programs to raise awareness of the increasing hypertension prevalence. For instance, in May 2023, the Ministry of Health and Prevention (MoHAP) UAE launched a national campaign for the early detection of hypertension. By 2030, UAE plans to reduce the prevalence of high blood pressure by 30%. Hence, increasing recommendations from government bodies will be key drivers for the global market.

The global market is experiencing innovation driven by the adoption of digital technology in the healthcare ecosystem. In the Europe region, countries are integrating medical services to improve healthcare facilities across multiple countries, which is driving the need for digital technologies. For instance, in June 2022, Nordic countries launched Nordic Interoperability Project (NIP) which aims to enable healthcare service providers in Sweden, Denmark, Norway, Finland, and Iceland to evaluate an integrated digital medical ecosystem focused on self-management and preventive care. Additionally, a proposal from the European Commission in May 2022 plans to create a European Health Data Space, which will harness the medical data of nearly 450 million people, thereby establishing cross-border digital healthcare connectivity. Increasing health monitoring through digital platforms will increase the adoption of general & preventive tests over the forecast period.

The availability of health insurance coverage that includes preventive care benefits encourages individuals to undergo routine check-ups, thereby driving market growth. For instance, as per the U.S. CDC, private health insurance in the U.S. covers around 66% of the insured population. In recent years, there has been a shift in insurance policies to prioritize preventive care. Most insurance providers now include preventive care services, such as health check-ups, vaccinations, and screenings, as part of their coverage at no additional cost. Furthermore, insurance companies require policyholders to undergo medical risk assessments as part of the underwriting process. These assessments typically involve health check-ups and help insurers assess the individual's wellness and determine appropriate coverage and premiums. Hence, underwriting processes and growing awareness of preventive care are anticipated to drive market growth

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

• The global cancer biopsy market size was valued at USD 30.05 billion in 2023 and is projected to grow at a CAGR of 8.11% from 2024 to 2030.

• The global pediatric allergy diagnostics market size was estimated at USD 2.44 billion in 2023 and is projected to grow at a CAGR of 10.1% from 2024 to 2030.

Key Health Check-up Company Insights

The key players operating in the health check-up industry are enhancing healthcare services and increasing strategic initiatives such as collaboration between government and private companies to enhance the efficiency and effectiveness of medical screening services. Moreover, the increasing introduction of direct-to-customer tests is further anticipated to fuel the market growth over the forecast period. For instance, in February 2023, Hurdel launched a Vitamin D test in the U.S., which will be sold on the company’s online store. Furthermore, the preventive test will allow the physicians to discuss concerns over chronic conditions and wellness. Some prominent players in global health check-up market include:

Quest Diagnostics Incorporated

Laboratory Corporation of America Holdings

SYNLAB International GmbH

OPKO Health, Inc. (BioReference Health, LLC.)

Eurofins Scientific

UNILABS

Sonic Healthcare Limited

ARUP Laboratories

Q2 Solutions

LalPathLabs.com

Order a free sample PDF of the Health Check-up Market Intelligence Study, published by Grand View Research.